Targeting angiopoietin-2 as a novel treatment option for kidney fibrosis

Area of Science:

• Nephrology
• Vascular Biology
• Immunology

Background:

• Kidney fibrosis is a significant complication of chronic kidney disease (CKD) with limited therapeutic options.
• Angiopoietin-2 (ANGPT2), a vascular growth factor, has been implicated in various disease processes.

Purpose of the Study:

• To investigate the role of angiopoietin-2 in the pathogenesis of kidney fibrosis and dysfunction associated with chronic kidney disease.
• To explore the potential of targeting angiopoietin-2 as a therapeutic strategy for CKD.

Main Methods:

• Quantified plasma and kidney angiopoietin-2 levels in CKD patients and disease models.
• Assessed the effects of angiopoietin-2 on kidney cells and its interaction with angiopoietin-1.
• Evaluated angiopoietin-2's impact on CC chemokine ligand 2 (CCL2)-mediated damage, endothelial cell apoptosis, vascular rarefaction, inflammation, and fibrosis in vivo and in vitro.

Main Results:

• Plasma and kidney angiopoietin-2 levels were found to be elevated in patients and mice with kidney disease.
• Angiopoietin-2 was shown to counteract the protective effects of angiopoietin-1.
• Angiopoietin-2 promoted kidney damage, endothelial cell apoptosis, vascular rarefaction, inflammation, and fibrosis, partly via CCL2 signaling.

Conclusions:

• Elevated angiopoietin-2 contributes to kidney damage and fibrosis in chronic kidney disease.
• Therapeutic inhibition of angiopoietin-2 presents a promising novel approach for treating CKD-associated pathologies.